{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:43:38Z","timestamp":1786985018915,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.bbmt.2018.06.025","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T12:56:20Z","timestamp":1529931380000},"page":"1961-1964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation"],"prefix":"10.1016","volume":"24","author":[{"given":"Keith M.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet S.","family":"Majhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bredeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie J.","family":"Crofford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Georges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Storek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. William","family":"St. Clair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.06.025_bib0001","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0002","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0003","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1002\/art.39748","article-title":"Review: Hematopoietic stem cell transplantation for scleroderma: effective immunomodulatory therapy for patients with pulmonary involvement","volume":"68","author":"Sullivan","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0004","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0005","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0006","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0007","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0008","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0009","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.bbmt.2014.12.030","article-title":"Guidelines for defining and implementing standard episode of care for hematopoietic stem cell transplantation within the context of clinical trials","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0010","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/rheumatology\/ket464","article-title":"Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations","volume":"53","author":"Henes","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0011","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","article-title":"Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis","volume":"381","author":"Burt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0012","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3899\/jrheum.110868","article-title":"Optimization of autologous stem cell transplantation for systemic sclerosis\u2014a single-center longterm experience in 26 patients with severe organ manifestations","volume":"39","author":"Henes","year":"2012","journal-title":"J Rheum"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0013","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2009.013458","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases","volume":"95","author":"Farge","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0014","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ard.2007.071464","article-title":"Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis","volume":"67","author":"Vonk","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0015","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study","volume":"110","author":"Nash","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0016","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1705782","article-title":"Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis","volume":"40","author":"Oyama","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0017","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Del Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0018","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V100.5.1602.h81702001602_1602_1610","article-title":"High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes","volume":"100","author":"McSweeney","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0019","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/ard.60.6.577","article-title":"Phase I\/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease","volume":"60","author":"Binks","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0020","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/rheumatology\/keq414","article-title":"Analysis of immune reconstitution after autologous CD34+ stem\/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells","volume":"50","author":"Tsukamoto","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0021","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.bbmt.2012.06.003","article-title":"Transplantation for autoimmune diseases in North and South America: a report of the Center for International Blood and Marrow Transplant Research","volume":"18","author":"Pasquini","year":"2012","journal-title":"Biology Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0022","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0140-6736(05)64864-7","article-title":"Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation","volume":"349","author":"Tyndall","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0023","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0024","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.bbmt.2018.06.025_bib0026","first-page":"198","article-title":"Autologous stem cell transplantation in systemic sclerosis: a systematic review","volume":"35(","author":"Host","year":"2017","journal-title":"Clin Exper Rheum"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0027","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","article-title":"Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis","volume":"24","author":"Shouval","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0028","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0029","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2017.56","article-title":"Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners","volume":"52","author":"Farge","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.06.025_bib0030","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.bbmt.2017.05.018","article-title":"Manufacture of autologous CD34(+) selected grafts in the NIAID-sponsored HALT-MS and SCOT multicenter clinical trials for autoimmune diseases","volume":"23","author":"Keever-Taylor","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118303628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118303628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:03:05Z","timestamp":1761058985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118303628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1083879118303628"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.025","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}